We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Generative AI Demonstrates Expert-Level Pathological Assessment of Lung Cancer

By LabMedica International staff writers
Posted on 05 Aug 2025

Lung adenocarcinoma is one of the most difficult cancers to diagnose accurately, requiring pathologists to spend extensive time examining tissue samples under microscopes to determine tumor grades and predict outcomes. More...

This manual process often leads to variability in assessments, as different pathologists may interpret subtle histological features differently. These inconsistencies pose a serious challenge in delivering timely, standardized diagnoses. In many parts of the world, access to experienced pathologists is also limited, creating a gap in care quality. Now, a new study has demonstrated how generative artificial intelligence (AI) could overcome these challenges by delivering fast, accurate, and reproducible assessments that rival expert-level performance.

In the study, researchers at Southern Medical University's Zhujiang Hospital (Guangzhou, China) tested three advanced GenAI models—GPT-4o, Claude-3.5-Sonnet, and Gemini-1.5-Pro. They analyzed 310 diagnostic slides from The Cancer Genome Atlas and 182 slides from independent medical institutions to evaluate the performance of these models. The GenAI systems were able to identify cancer patterns and grade tumors with notable accuracy, with Claude-3.5-Sonnet achieving an average of 82.3% accuracy in differentiating between cancer grades. The models operate by extracting key pathological features—such as tumor necrosis, inflammatory responses, and cellular patterns—and quantifying them with precision, transforming subjective visual interpretation into measurable metrics. The researchers went on to develop a sophisticated prognostic model that combines GenAI-extracted pathological features with clinical information, successfully predicting patient outcomes across multiple validation studies. Their model identified 11 key histological features and 4 clinical variables that together provide a comprehensive risk assessment for patients.

The findings, published in the International Journal of Surgery, confirmed that GenAI-enabled analysis could consistently replicate diagnostic evaluations, even when applied repeatedly to the same tissue samples. The models completed assessments in minutes, offering massive time savings for clinical workflows. They also revealed previously underappreciated prognostic factors—such as interstitial fibrosis, papillary patterns, and lymphocytic infiltration—highlighting the potential of AI to uncover new dimensions of cancer pathology. By providing scalable, consistent, and expert-level diagnostics, the technology promises to democratize access to high-quality care and reshape cancer treatment strategies. Future research will likely explore broader implementation and deeper integration into clinical decision-making systems.

 


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gel Cards
DG Gel Cards
New
Human Estradiol Assay
Human Estradiol CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Industry

view channel
Image: Alzheimer’s Association has released its first clinical practice guideline for blood-based biomarker tests (Photo courtesy of Alzheimer’s Association)

New Clinical Guidelines Recommend Use of Blood Tests Instead of Brain Scans for Alzheimer’s Diagnosis

Alzheimer’s disease is a progressive neurodegenerative condition that remains challenging to diagnose early and accurately, particularly in individuals with cognitive impairment. Despite the availability... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.